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OBJECTIVE—Insulin resistance is commonly associated with
obesity. Studies conducted in obese mouse models found that
endoplasmic reticulum (ER) stress contributes to insulin resis-
tance, and treatment with tauroursodeoxycholic acid (TUDCA),
a bile acid derivative that acts as a chemical chaperone to
enhance protein folding and ameliorate ER stress, increases
insulin sensitivity. The purpose of this study was to determine
the effect of TUDCA therapy on multiorgan insulin action and
metabolic factors associated with insulin resistance in obese
men and women.
RESEARCH DESIGN AND METHODS—Twenty obese sub-
jects ([means  SD] aged 48  11 years, BMI 37  4 kg/m
2) were
randomized to 4 weeks of treatment with TUDCA (1,750 mg/day)
or placebo. A two-stage hyperinsulinemic-euglycemic clamp pro-
cedure in conjunction with stable isotopically labeled tracer
infusions and muscle and adipose tissue biopsies were used to
evaluate in vivo insulin sensitivity, cellular factors involved in
insulin signaling, and cellular markers of ER stress.
RESULTS—Hepatic and muscle insulin sensitivity increased by
30% (P  0.05) after treatment with TUDCA but did not change
after placebo therapy. In addition, therapy with TUDCA, but not
placebo, increased muscle insulin signaling (phosphorylated
insulin receptor substrate
Tyr and Akt
Ser473 levels) (P  0.05).
Markers of ER stress in muscle or adipose tissue did not change
after treatment with either TUDCA or placebo.
CONCLUSIONS—These data demonstrate that TUDCA might
be an effective pharmacological approach for treating insulin
resistance. Additional studies are needed to evaluate the target
cells and mechanisms responsible for this effect. Diabetes 59:
1899–1905, 2010
T
he ability of insulin to decrease hepatic glucose
production, suppress adipose tissue lipolytic
rate, and stimulate skeletal muscle glucose up-
take is critical for normal metabolic function.
Obesity is an important cause of multiorgan insulin resis-
tance (1–3), and insulin sensitivity decreases linearly with
increasing BMI (4,5). Insulin resistance has important
clinical implications because it is involved in the patho-
genesis of many of the metabolic complications associated
with obesity. The precise mechanisms responsible for the
link between obesity and insulin resistance are not known
but likely involve alterations in fatty acid metabolism,
excess triglyceride accumulation in the liver and muscle
(6–11), and systemic low-grade inﬂammation (12–14).
Recently, endoplasmic reticulum (ER) stress has been
identiﬁed as a contributor to insulin resistance associated
with obesity in experimental models (15,16). The ER is
responsible for the synthesis, folding, and trafﬁcking of
secretory and membrane proteins. Disruption of ER ho-
meostasis results in an adaptive unfolded protein response
(UPR), which aims to restore ER folding capacity and
mitigate stress. ER stress can also inhibit insulin signaling,
at least in part, by activating the c-Jun NH2-terminal kinase
(JNK) pathway through inositol-requiring enzyme (IRE)-1
(15,17–20) or RNA-dependent protein kinase (PKR)-medi-
ated mechanisms (21). Increased ER stress is associated
with impaired insulin action in obese mice (15), and
chemical or genetic amelioration of this stress improves
insulin sensitivity and glucose homeostasis (18). Increased
ER stress in liver and adipose tissue and insulin resistance
are also associated with obesity in humans (22,23),
whereas weight loss decreases ER stress and improves
insulin sensitivity (22).
Tauroursodeoxycholic acid (TUDCA) is a bile acid
derivative that has been used in Europe to treat choleli-
thiasis and cholestatic liver disease. TUDCA can also act
as a chemical chaperone to enhance protein folding and
protect cells against ER stress (18). In obese mice, paren-
teral TUDCA treatment reduces ER stress, improves
systemic insulin resistance, and decreases intrahepatic
triglyceride (IHTG) content (18). Although data from stud-
ies conducted in animal models and cell systems demon-
strate beneﬁcial metabolic effects, the effect of TUDCA on
insulin action has not been studied in human subjects.
The purpose of the present study was to determine
whether chemical interventions targeting the ER stress
pathway results in metabolic beneﬁts in people. Accord-
ingly, we conducted a randomized controlled trial in
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treatment with TUDCA on insulin sensitivity in the liver
(glucose production), muscle (glucose uptake), and adi-
pose tissue (lipolysis). We hypothesized that treatment
with TUDCA would improve multiorgan insulin signal-
ing and sensitivity and other metabolic factors associ-
ated with insulin resistance. The hyperinsulinemic-
euglycemic clamp procedure, in conjunction with stable
isotopically labeled tracer infusions, was used to deter-
mine in vivo insulin sensitivity, and adipose tissue and
skeletal muscle biopsies were obtained to assess ER stress
markers, phosphorylation of JNK, and components of the
insulin-signaling pathway before and after 4 weeks of
treatment with TUDCA or placebo.
RESEARCH DESIGN AND METHODS
Twenty obese adults ([means  SD] 8 men and 12 women, aged 48  11 years,
BMI 37  4 kg/m
2) participated in this single-blinded, randomized, placebo-
controlled trial. All subjects were insulin resistant, deﬁned as a homeostasis
model assessment of insulin resistance (HOMA-IR) value of 3.0 at the time
of screening (24). Subjects completed a comprehensive medical evaluation,
including a detailed history, physical examination, blood tests, and a 2-h oral
glucose tolerance test. Those who had diabetes, chronic liver disease other
than nonalcoholic fatty liver disease (NAFLD), severe hypertriglyceridemia
(fasting serum triglyceride concentrations 400 mg/dl), and those who
smoked cigarettes or were taking medications known to alter glucose or lipid
metabolism were excluded. We purposely studied obese subjects who were
insulin resistant but did not have diabetes to provide the best chance for
detecting an improvement in insulin sensitivity by TUDCA therapy, without
the potential confounding inﬂuences of treatment with diabetes medications
and differences in glucose control among study subjects. All subjects were
sedentary (regular exercise 1 h/week and 1 time/week) and weight stable
(2% weight change) for at least 3 months before the study. Subjects provided
written informed consent before participating in this study, which was
approved by human research protection ofﬁce of Washington University
School of Medicine in St. Louis, Missouri.
Body composition. Body composition analyses were performed 1 week
before the hyperinsulinemic-euglycemic clamp procedure was performed.
Body fat mass and fat-free mass were determined by using dual-energy X-ray
absorptiometry (QDR 4500; Hologic, Waltman, MA). Abdominal subcutaneous
adipose tissue and intra-abdominal adipose tissue volumes were determined
by using magnetic resonance imaging; the sum of 10 axial images of 1-cm
thickness, beginning at the L4–L5 interspace and extending proximally, was
used to determine each fat depot volume. Intrahepatic triglyceride content
was determined by using magnetic resonance spectroscopy (3T Siemens
Magnetom Trio scanner; Siemens, Erlanger, Germany); three 15  15 
15–mm voxels were examined in each subject, and the values were averaged
to provide an estimate of the percent of total liver volume comprised of
triglycerides (25).
Hyperinsulinemic-euglycemic clamp procedure. Subjects were admitted
to the clinical research unit at Washington University School of Medicine in
the afternoon on the day before the clamp procedure. At 1800 h, they
consumed a standard meal containing 12 kcal/kg fat-free mass, with 55% of
total energy provided as carbohydrates, 30% as fat, and 15% as protein.
Subjects then fasted, except for water, until completion of the clamp
procedure the next day. At 0500 h the following morning, a catheter was
inserted into a forearm vein to infuse stable isotopically labeled tracers
(purchased from Cambridge Isotope Laboratories, Andover, MA), dextrose
and insulin. A second catheter was inserted into the contralateral radial artery
to obtain blood samples. Radial artery cannulation was not successful in four
subjects, so a catheter was inserted into a hand vein, which was heated to
55°C by using a thermostatically controlled box to obtain arterialized blood
samples (26). At 0600 h, a primed-continuous infusion of [6,6-
2H2]glucose
(priming dose 22.5 mol/kg body wt; infusion rate 0.25 mol/kg body wt/min)
was started and maintained for 9.5 h. At 0800 h, a continuous infusion of
[2,2-
2H2]palmitate (infusion rate 0.035 mol/kg body wt/min) bound to 25%
human albumin was started and maintained for 7.5 h. At 0930 h, 3.5 h after
starting the glucose tracer infusion, a two-stage hyperinsulinemic-euglycemic
clamp procedure was started and continued for 6 h. During stage 1 of the
clamp procedure (3.5–6.5 h), insulin was infused at a rate of 7 mU/m
2 body
surface area [BSA]/min (initiated with a priming dose of 28 mU/m
2 BSA/min
for 5 min and then 14 mU/m
2 BSA/min for another 5 min) for 3 h. During stage
2 of the clamp procedure (6.5–9.5 h), the rate of insulin infusion was increased
to 50 mU/m
2 BSA/min (initiated with a priming dose of 200 mU/m
2 BSA/min
for 5 min and then 100 mU/m
2 BSA/min for another 5 min). These insulin
infusion rates were chosen to evaluate adipose tissue insulin sensitivity
(low-dose insulin infusion to submaximally suppress lipolysis of adipose
tissue triglycerides) and skeletal muscle insulin sensitivity (high-dose insulin
infusion to stimulate muscle glucose uptake) (27). Euglycemia was main-
tained at a blood concentration of 5.6 mmol/l (100 mg/dl) by infusing
20% dextrose enriched to 2.5% with [6,6-
2H2]glucose. The infusion rate of
[6,6-
2H2]glucose was reduced by 50% of basal during stage 1 and by 75%
of basal during stage 2 of the clamp procedure to account for the ex-
pected decline in endogenous glucose production. The infusion rate of
[2,2-
2H2]palmitate was reduced by 50% of basal during stage 1 to account
for the expected decline in lipolytic rate.
Blood samples were obtained before the start of the tracer infusions to
determine background plasma tracer-to-tracee ratios of glucose and palmitate
and every 10 min during the ﬁnal 30 min of the basal period and stages 1 and
2 of the clamp procedure to determine glucose, free fatty acid (FFA), and
insulin concentrations and substrate kinetics. Blood samples were collected
in chilled heparinized tubes to determine glucose and insulin concentration.
All other blood samples were collected in chilled tubes containing EDTA.
Samples were placed on ice, and plasma was separated by centrifugation
within 30 min of collection. Plasma samples were stored at 80°C until ﬁnal
analyses were performed.
Subcutaneous abdominal adipose tissue and muscle tissue (vastus lateralis
portion of the quadriceps femoris) were obtained during the basal period to
determine the expression and regulation of ER stress markers. Additional
muscle tissue was obtained at 30 min after starting stage 2 of the clamp
procedure to determine the levels and the extent of phosphorylation of JNK
and elements of the insulin-signaling pathway. The biopsy sites were cleaned
and draped, and the skin and underlying tissues were anesthetized with
lidocaine. A small (0.5 cm) skin incision was made with a scalpel; adipose
tissue was aspirated through a 4-mm liposuction cannula, and muscle tissue
was obtained by using Tilley-Henkel forceps (Sontec Instruments, Centennial,
CO). Muscle and adipose tissue samples were immediately rinsed in ice-cold
saline, frozen in liquid nitrogen, and stored at 80°C until ﬁnal analyses were
performed.
Intervention. After the baseline clamp procedure was completed, each
subject was randomized to 4 weeks of oral treatment with either TUDCA
(1,750 mg/day) or placebo. Both TUDCA and placebo were kindly provided by
Bruschettini S.r.l (Genova, Italy). During the 4-week intervention period,
subjects were seen every week to review any study-related issues, reinforce
treatment compliance, check body weight, and assess vital signs. After 4
weeks of treatment, the body composition analyses and clamp procedure
performed at baseline were repeated. Stage 2 of the clamp procedure was not
completed in 2 of 10 subjects who received TUDCA treatment because of
technical difﬁculties in obtaining blood samples. Treatment with drug or
placebo was continued until all evaluations were ﬁnished.
Sample processing and analyses. Plasma glucose concentration was deter-
mined by using an automated glucose analyzer (YSI 2300 STAT Plus; Yellow
Springs Instruments, Yellow Springs, OH). Plasma FFA concentrations were
quantiﬁed by using gas chromatography (HP 5890 Series II GC; Hewlett-
Packard, Palo Alto, CA) (28). Plasma insulin concentration was measured by
using a chemiluminescent immunometric assay (Immulite 1000; Diagnostic
Products, Los Angeles, CA). Plasma C-reactive protein and interleukin-6
concentrations were measured by using commercially available high-sensitiv-
ity immunoassays (R&D Systems, Minneapolis, MN). Total and high–molecu-
lar weight adiponectin concentrations were determined by using fast protein
liquid chromatography (AKTA FPLC system; GE Healthcare) and ﬂuorescent
Western blotting (LI-COR Biotechnology, Lincoln, NE), as previously de-
scribed (29). Plasma glucose and palmitate tracer-to-tracee ratios were
determined by using gas chromatography/mass spectroscopy (MSD 5973
system with capillary column; Hewlett-Packard), as previously described (30).
To determine the activation of the insulin signaling and the JNK pathways
in muscle and adipose tissue, we measured the site-speciﬁc phosphorylation
of insulin receptor substrate (IRS)-1, Akt, and JNK. Tissue samples were
cryopulverized, and the powdered tissue transferred to a tube containing cell
lysis solution (Cell Signaling, Beverly, MA) and homogenized using a polytron
(PowerGen 125; Fisher, Pittsburgh, PA). Homogenates were spun for 15 min
at 2000g at 4°C to pellet insoluble material. The total protein concentration in
the supernatant was measured (DC Protein Assay; Bio-Rad, Hercules, CA),
and 25–50 g protein were electrophoresed by SDS-PAGE and transferred to
nitrocellulose membranes. Blots were probed with polyclonal antibodies
directed against total Akt, Akt
Ser473, total JNK, and JNK
Thr183/Tyr185 (all Cell
Signaling, Beverly, MA) in Western analyses. To evaluate IRS-1 tyrosine
phosphorylation, blots were concurrently probed with a rabbit polyclonal
antibody against IRS-1 (gift of Mike Mueckler, Washington University School
of Medicine, St. Louis, MO) and a mouse monoclonal phospho-tyrosine
antibody (Cell Signaling, Danvers, MA) and then incubated with secondary
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Detection was performed with the LiCor dual-color system (Li-Cor Bio-
sciences, Lincoln, NE). All band intensities were visualized and quantiﬁed by
using the LiCor system and Odyssey 3.0 software, and phosphorylation levels
were expressed as a function of total protein levels.
Real-time quantitative PCR was performed as previously described to
determine the mRNA expression of ER stress markers (glucose-regulated
protein 78 [Grp78], spliced X-box binding protein-1 [XBP-1], and C/EBP
homologous protein [CHOP]) in adipose tissue (22). Frozen adipose tissue
samples were homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA), and
cDNA synthesis was performed by using 1 g of sample RNA reverse
transcribed with high-capacity cDNA archive system (Applied Biosystems,
Foster City, CA); quantitative RT-PCR was performed by using SybrGreen
reagent in an ABI 7300 real-time PCR system (Applied Biosystems). The
mRNA expression of ER stress markers were normalized to 18S rRNA. The
protein expression of homocysteine-induced ER protein (HERP) and the con-
centrations of eukaryotic elongation initiation factor 2 (eIF2) phosphory-
lated at serine 52 and JNK phosphorylated at threonine 183 and tyrosine 185
in adipose tissue were determined by Western analyses using rabbit poly-
clonal anti–p-eIF2 (Invitrogen) and mouse monoclonal anti–p-JNK (Cell
Signaling, Danvers, MA) antibodies as previously described (22). Anti-HERP
antibody was a gift from Dr. Yasuhiko Hirabayashi of Tohoku University
(Sendai Japan). The band intensities of p-(eIF2), p-JNK, and HERP were
normalized to actin.
Calculations. Isotopic steady-state conditions were achieved during the ﬁnal
30 min of the basal period and stages 1 and 2 of the clamp procedure, so the
Steele equation for steady-state conditions was used to calculate glucose rate
of appearance (Ra), glucose rate of disappearance (Rd), and palmitate Ra (31).
The hepatic insulin sensitivity index was determined as the reciprocal of the
hepatic insulin resistance index, which was calculated as the product of the
basal hepatic glucose production rate (in mol/min) and basal plasma insulin
concentration (in U/ml) (32). Adipose tissue insulin sensitivity was assessed
by calculating the relative decrease from basal in palmitate Ra into plasma
during stage 1 of the clamp procedure. Skeletal muscle insulin sensitivity was
assessed by calculating the relative increase from basal in glucose Rd from
plasma during stage 2 of the clamp procedure. The HOMA-IR score was
calculated as the product of fasting plasma insulin (in mU/l) and glucose (in
mmol/l) concentrations divided by 22.5 (24).
Statistical analyses. Statistical analyses were performed by using SPSS for
Windows (version 16.0; SPSS, Chicago, IL). Results are reported as means 
SD (normally distributed datasets) or medians and quartiles (skewed data-
sets). Two-way repeated-measures ANOVA was used to determine whether
the changes in outcomes (normally distributed datasets) in response to either
TUDCA or placebo treatment were different. Skewed data sets were evaluated
by using nonparametric analyses. A P value 0.05 was considered statistically
signiﬁcant. Results are reported as means  SD (normally distributed
datasets) or medians and quartiles (skewed datasets).
Based on data on glucose kinetics we obtained in obese subjects previously
(33), we estimated that a sample size of 10 participants per group would allow
us to detect a 25% difference in insulin sensitivity after treatment between
groups, with an  value of 0.05 and power of 80% (	
0.2). A difference in
insulin sensitivity of this magnitude is clinically meaningful because it
represents the lower end of the observed effect of current treatment strategies
for insulin resistance, such as moderate weight loss (33) or pharmacotherapy
(e.g., metformin and thiazolidinediones) (34–41).
RESULTS
Subject characteristics, metabolic variables, and
body composition. Subjects randomized to receive
TUDCA and placebo were similar in age, sex, BMI, and
body composition (Table 1). Body weight, total body fat,
and fat distribution (intra-abdominal fat volume and
IHTG content) did not change after 4 weeks of treat-
ment with either TUDCA or placebo (Table 1). Baseline
(before treatment) plasma concentrations of glucose,
insulin, FFAs, triglycerides, aspartate aminotransferase,
alanine aminotransferase, total adiponectin, high–mo-
lecular weight adiponectin, and markers of inﬂammation
were not different between groups and did not change
after either TUDCA or placebo treatment (Table 1). The
HOMA-IR score did not change after placebo treatment
but was 20% lower after TUDCA treatment (Table 1);
however, the decrease in HOMA-IR after TUDCA therapy
was not statistically signiﬁcant.
Insulin sensitivity assessed by using the hyperinsu-
linemic-euglycemic clamp technique. During the hyper-
insulinemic-euglycemic clamp procedure, euglycemia was
maintained at 100 mg/dl in all subjects (average plasma
glucose concentration: 100.0  2.1 mg/dl during stage 1
and 102.0  2.7 mg/dl during stage 2 of the clamp
procedure) and plasma insulin concentration increased to
TABLE 1
Subjects’ characteristics, metabolic variables, and body composition
Placebo TUDCA
Before After Before After
n (male/female) 10 (4/6) — 10 (4/6) —
Age (years) 49  14 — 47  9—
BMI (kg/m
2) 37  53 8  53 5  33 5  3
Total body mass (kg) 109  18 110  17 100  12 100  12
Fat mass (%) 39  73 9  73 9  83 9  8
Subcutaneous abdominal fat volume (cm
3) 5,087  1,749 4,999  1,672 4,803  1,202 4,716  1,188
Intra-abdominal fat volume (cm
3) 2,146  789 2,172  716 2,724  846 2,818  924
IHTG content (%) 14.0  10.7 13.7  9.6 8.2  5.5 9.3  7.2
HOMA-IR 4.2  1.8 4.3  1.7 4.4  2.7 3.8  3.4
Plasma concentrations
Glucose (mg/dl) 97  99 7  10 96  99 4  5
Insulin (U/ml) 18  71 8  71 9  12 16  15
FFAs (mmol/l) 0.59  0.13 0.63  0.15 0.62  0.15 0.62  0.19
Triglycerides (mg/dl) 154  52 145  77 136  67 141  66
AST (IU/l) 25.9  10.3 27.9  14.5 22.4  5.9 22.5  6.1
ALT (IU/l) 30.3  24.7 35.6  34.9 26.9  9.6 24.6  8.1
CRP (mg/l) 5.67  5.69 5.00  3.87 5.40  4.11 4.43  2.94
IL-6 (pg/ml) 2.60  0.95 2.44  0.86 2.32  0.65 2.60  1.17
Total adiponectin (mg/l) 6.7  3.8 6.9  4.6 8.3  3.1 8.3  3.1
HMW adiponectin (mg/l) 2.2  2.6 2.2  2.9 3.1  1.9 3.4  2.4
Data are means  SD. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; HMW, high molecular
weight; IL, interleukin.
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stage 2.
The hepatic insulin sensitivity index increased by 30%
after TUDCA treatment but was not affected by placebo
therapy (Fig. 1A). Glucose Rd increased by 150% (P 
0.001) from basal values during stage 2 of the clamp
procedure in both the TUDCA and placebo groups before
treatment. Compared with baseline (pretreatment) values,
the increase in glucose Rd above basal values during stage
2 was 34  23% greater after treatment with TUDCA (P 
0.05) but did not change after treatment with placebo (Fig.
1B). Insulin infusion suppressed palmitate Ra by 50% in
both TUDCA and placebo groups before treatment, and
this remained the same after treatment with either TUDCA
or placebo (Fig. 1C).
Consistent with our kinetic data, TUDCA therapy in-
creased insulin signaling in muscle but not adipose tissue.
Compared with placebo treatment, TUDCA treatment in-
creased insulin-stimulated phosphorylation of IRS
Tyr and
Akt
Ser473 in muscle (both P  0.05) (Fig. 2). In contrast,
TUDCA therapy did not alter insulin-stimulated phosphor-
ylation of IRS
Tyr and Akt
Ser473 in adipose tissue (data not
shown). No difference in skeletal muscle phosphorylation
of JNK
Thr183/Tyr185 was detected between subjects treated
with placebo or TUDCA (Fig. 2).
ER stress markers in muscle and adipose tissue.
Adipose tissue mRNA expression of spliced XBP-1, Grp78,
and CHOP (Fig. 3A) and protein levels of HERP,
eIF2
Ser52, and JNK
Thr183/Tyr185 (Fig. 3B) were not affected
by either placebo or TUDCA treatment. Spliced XBP-1,
Grp78, and CHOP mRNA expression in skeletal muscle
were very low (below the limit of reliable detection for
spliced XBP-1) and did not change after TUDCA treatment
(data not shown).
DISCUSSION
Data from recent studies (15,18,22,23) conducted in both
rodent models and human subjects have demonstrated
that obesity is associated with liver and adipose tissue but
not muscle ER stress. Treating obese mice with TUDCA,
which acts as a chemical chaperone that reduces ER stress
in liver and adipose tissue, results in improved insulin
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ever, the use of agents that can decrease ER stress to treat
obesity-associated insulin resistance has not been evalu-
ated in people. Accordingly, we conducted a randomized
controlled trial to determine the effect of 4 weeks of
treatment with TUDCA on multiorgan insulin sensitivity
and factors involved in regulating insulin action in obese
subjects with insulin resistance. Our data demonstrate
that TUDCA therapy increases hepatic and muscle insulin
action in vivo with a concomitant increase in the phos-
phorylation of components of the muscle insulin-signaling
pathway. Moreover, the magnitude of the improvement in
hepatic and muscle insulin sensitivity (both 30%) is
similar to the insulin-sensitizing effects of currently avail-
able diabetes medications, such as thiazolinediones and
metformin (35–41). However, we did not detect an effect
of TUDCA on adipose tissue insulin sensitivity or ER
stress, making it unlikely that a reduction in adipocyte ER
stress was responsible for the effect on insulin action in
this trial. These data suggest that TUDCA therapy might
provide a novel pharmacological approach for improving
glucose homeostasis in insulin-resistant obese people.
The precise cellular mechanisms responsible for the
improvement in hepatic insulin sensitivity after TUDCA
therapy are not clear. Data from studies conducted in
human hepatocyte cultures have shown that TUDCA acti-
vates Akt and its downstream targets via a G-protein–
coupled receptor–dependent mechanism (42,43). In
addition, activation of the nuclear farnesoid X receptor
(FXR) by bile acids or FXR agonists improves insulin
sensitivity in vitro in cell systems and in vivo in animal
models (44,45). However, TUDCA, unlike some other bile
acids, is a relatively poor substrate for FXR (46). In animal
models and cultured liver cells, TUDCA treatment can
suppress ER stress and increase insulin signaling (18).
Therefore, it is possible that TUDCA therapy affected
hepatic ER stress in our subjects, but we did not obtain
liver tissue in our subjects to directly evaluate this
possibility.
The mechanisms responsible for the TUDCA-induced
improvement in skeletal muscle insulin sensitivity and
insulin signaling in our subjects and in the previous study
(18) conducted in mice are also not clear. In contrast with
adipose tissue and liver, ER stress indicators are not
increased in skeletal muscle from obese mice (15,18) or
obese people (23), and TUDCA treatment did not affect
muscle ER stress markers in our study. In addition, muscle
does not express the FXR (46), which precludes the
possibility of an FXR-mediated improvement in muscle
insulin action. However, G-protein receptors are ex-
pressed ubiquitously, so some of the effects of TUDCA in
muscle might be mediated by G-protein receptor activa-
tion of Akt.
Although we found that TUDCA therapy improved he-
patic and muscle insulin sensitivity, we did not ﬁnd a
signiﬁcant effect of TUDCA therapy on HOMA-IR and
many of the metabolic variables associated with insulin
resistance, such as plasma glucose, insulin, and FFA
concentrations. It is likely that these measures were not
adequate to detect an effect of TUDCA, which required a
more sensitive assessment of insulin action by using stable
isotopically labeled tracers and the hyperinsulinenmic-
euglycemic clamp procedure.
Unlike data obtained from mouse models (18), we did
not detect an effect of TUDCA therapy on adipose tissue
insulin sensitivity or signaling or the expression of adipose
tissue ER stress markers. Several factors might be respon-
sible for the apparent difference observed after TUDCA
therapy in mice and our study in human subjects. First, it
is possible that the amount of TUDCA we gave our
subjects, which is the maximum dose used to treat biliary
disease, was insufﬁcient to generate changes in adipose
tissue ER stress; in the previous study, 30 times more
TUDCA relative to body weight was given to mice than to
our subjects. Second, TUDCA was given intraperitoneally
in the mice but orally to our subjects. It is likely this
difference in route of administration further limited the
systemic availability of TUDCA in our subjects, because
TUDCA is effectively metabolized by the liver and there is
minimal splanchnic escape of bile acid conjugates into
the systemic circulation (47). Finally, the expression of
transporters responsible for TUDCA tissue uptake is
very low in most extrahepatic tissues (48,49), so large
plasma concentrations might be needed to achieve
adequate tissue uptake to affect intracellular function.
These pharmacokinetic factors raise the possibility that
adipose tissue did not get sufﬁcient exposure to orally
administered TUDCA to affect ER stress in our subjects.
Future studies with different dosing regimens are
needed to address this issue.
In summary, insulin resistance is involved in the patho-
genesis of the key metabolic disorders associated with
obesity (1–3,6–14). The results from the present study
demonstrate that TUDCA therapy increases liver and
muscle insulin sensitivity in obese, insulin-resistant sub-
jects. Additional studies are needed to determine the
speciﬁc cellular mechanisms responsible for this effect
and to determine the therapeutic potential of this class of
compounds for obese people with insulin resistance.
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